Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study

Ozdemir, Nuriye; Abali, Huseyin; Vural, Murat; YALÇIN, ŞUAYİB; Oksuzoglu, Berna; Civelek, Burak; Oguz, Dilek; Bostanci, Birol; Yalcin, Bulent; Zengin, Nurullah

doi:10.1007/s00280-014-2586-6

Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study

Copy For Citation

Ozdemir N., Abali H., Vural M., YALÇIN Ş., Oksuzoglu B., Civelek B., ...More

CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.74, no.6, pp.1139-1147, 2014 (SCI-Expanded)

Publication Type: Article / Article
Volume: 74 Issue: 6
Publication Date: 2014
Doi Number: 10.1007/s00280-014-2586-6
Journal Name: CANCER CHEMOTHERAPY AND PHARMACOLOGY
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.1139-1147
Hacettepe University Affiliated: Yes

Abstract

This phase II trial aimed to evaluate the efficacy and safety of docetaxel, cisplatin, and fluorouracil (DCF) combination in neoadjuvant setting in patients with locally advanced gastric adenocarcinoma.